Fast Food Causes Alzheimer's Disease, Makes Population Stupid Natural News.com, AZ - Nov 29, 2008 ...Alzheimer's Disease Research Center. They were attempting to test the effects of fast food and junk food on individuals with the apoE4 gene variant, ...
Health calendar Monroe News Star, LA - Alzheimer's ? 3 pm third Thursday of every month, Richardson Medical Center, 254 Louisiana 3048, Rayville. For more information, contact Katherine Kee, ...
Dr. Bill Elliott: Ginkgo biloba fails its test Marin Independent-Journal, CA - Within the study group 523 patients developed dementia, mostly Alzheimer's disease, including 246 patients who took the placebo pills and 277 patients who ...
Submitting to the Science of Prevention Wall Street Journal - Nov 25, 2008 But many of these developments may be a long way off, and genetic tests alone have limitations in terms of predicting disease. ...
Don?t Fire Until You See the Whites of Their Eyes The Epoch Times, NY - It affects close to 300000 Canadians, more Canadians than those who have breast cancer, prostate cancer, Parkinson?s disease, and Alzheimer?s disease...
Terry Grossman Recommended Health Checks and Prevention Next Big Future, CA - APOE2, APOE3, and APOE4 tests will help determine Alzheimer's risk. (About $90) 23andme offers $400 a test of about 80 genes based on a swab of your mouth.
International Conference on Alzheimer?s Disease Concludes HealthNews, CA - One study was on a blood test that detects a cell cycle defect in lymphocytes of people with Alzheimer's. The second study was for identifying and tracking ...
Experimental Alzheimer's drug shows early promise Dallas Morning News, TX - Aug 1, 2008 On Monday at the International Conference on Alzheimer's Disease, other researchers reported encouraging results from a test of a different experimental ...
Early Study Reveals New Drug Could Improve Executive Function in ... PharmaLive.com (press release), PA - Jul 30, 2008 LONDON, July 29, 2008--An early study has shown that the new drug PBT2 improves two indicators of executive function in patients with Alzheimer?s disease ...
Mild Cognitive Impairment Represents Early-Stage Alzheimer Disease - JC Morris, M Storandt, JP Miller, DW McKeel, JL … - Archives of Neurology, 2001 - Am Med Assoc ... type; and DAT, dementia of the Alzheimer type. ... programs investigating aging, MCI,
and early-stage AD ... process independent of neuropsychological test scores (even ...
[PDF]Metabolic reduction in the posterior cingulate cortex in very early Alzheimer's disease - S Minoshima, B Giordani, S Berent, KA Frey, NL … - Annals of Neurology, 1997 - deepblue.lib.umich.edu ... very early stage of the disease using regression analysis of cerebral metabolism
and mental status test results in probable Alzheimer?s disease patients with ... -
Cognitive test performance in detecting, staging, and tracking Alzheimer's disease - JJ Locascio, JH Growdon, S Corkin - Archives of Neurology, 1995 - archneur.highwire.org ... Cognitive test performance in detecting, staging, and ... cognitive deficits that
characterize Alzheimer's disease (AD ... deterioration to an early floor, consistent ... -
A potential noninvasive neurobiological test for Alzheimer's disease - LF Scinto, KR Daffner, D Dressler, BI Ransil, D … - Science, 1994 - sciencemag.org ... at autopsy or biopsy. There is a great need for an early, noninvasive, sensitive,
and easily administered diagnostic test of Alzheimer's disease. ...
Visual association test to detect early dementia of the Alzheimer type - J Lindeboom, B Schmand, L Tulner, G Walstra, C … - British Medical Journal, 2002 - jnnp.bmj.com ... PAPER. Visual association test to detect early dementia of the Alzheimer type. J
Lindeboom 1 , B Schmand 2 , L Tulner 3 , G Walstra 2 and C Jonker 4 ...
Source: Google Scholar
Skin Test Could Detect Alzheimer's Disease Early
MONDAY, Aug. 14 (HealthDay News) -- A simple skin test that would allow detection of Alzheimer's disease in its earliest stages is working its way to reality.
The work "is based on the hypothesis that Alzheimer's disease doesn't just affect the brain but affects the body systemically," said Dr. Daniel L. Alkon, a lead author of a report on the test published online this week in Proceedings of the National Academy of Sciences.
The test zeroes in on two forms of an enzyme involved in the degradation of amyloid, the protein that accumulates in the brain of someone with Alzheimer's, said Alkon, scientific director of the Blanchette Rockefeller Neurosciences Institute at the West Virginia University Health Sciences Center.
The presence of Alzheimer's disease is indicated by a steep imbalance in the ratio of the two forms of the enzyme, MAP kinase Erk, in skin cells that are exposed to bradykinin, an inflammation-related molecule, Alkon said. That imbalance is not seen in cells of people without dementia or those with other forms of dementia, he said.
The test produced good results when run on 60 tissue samples: 30 from a tissue bank, 30 from autopsy samples of people diagnosed with Alzheimer's disease, Alkon said.
"We have seen a correlation with the duration of the disease," he said. "The earlier it is done in the course of the disease, the larger is the abnormality."
An as-yet unpublished study of the test done on 100 people showed equally good results, Alkon said.
"We are ready to expand this to thousands," he added.
Such expanded testing is essential, said Dr. Samuel Gandy, director of Thomas Jefferson University's Farber Institute for Neurosciences and chief of the Alzheimer's Association medical and scientific advisory council.
The hypothesis behind the test "is, by no means, an accepted formulation, nor have they proved it," he said.
The presence of inflammation around the amyloid clumps that form in the brain of Alzheimer's patients is well known, Gandy said. "Whether there is inflammation elsewhere in the body hasn't been established. The idea that this might be a systemic process hasn't been thoroughly investigated," he added.
Gandy said the theory is "unconventional, but it certainly is something that can be investigated by others."
"Technically, it looks perfectly sound," Gandy said of the published paper. "But certainly nothing in science is accepted until it is replicated. The real test of the pudding will be if others do the same experiment and get the same results. It would have to be robustly reproducible before we change the way we think about Alzheimer's."
Having a test for early detection of Alzheimer's disease would be extremely valuable, both Alkon and Gandy said. "All the newest medications in clinical trials are aimed at the earliest stage of the disease," Gandy said.
"Drugs now are being tested on the basis of clinical diagnosis," Alkon said. "There is a major need for an early biomarker."
